Asthma, Inflammation and G Protein-coupled Receptors (GPCR)

Not Applicable

Completed

• Conditions: Asthma; COPD
• Interventions: Other: spirometry; Other: blood test

• Registration Number: NCT00793676
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

The G protein-coupled receptors (GPCRs) are a family of proteins expressed at the cell membrane. They are composed of 380 members involved in the important functions of the organism and are privileged therapeutic targets.Their expression is highly modulated depending on the metabolic state of the cells, in particular in pathological situations.our study proposes to determine whether GPCR expression modulation could be used as a biomarker, either prognostic or diagnostic, of treatments.To do so , the investigators will determine the expression profile of the 380 human GPCRs in human blood cell samples in two chronic inflammatory pulmonary diseases : asthma and COPD (chronic obstructive pulmonary disease ) . These have opposed inflammatory infiltrates : asthma is associated with eosinophil and Th2 lymphocyte infiltration whereas COPD shows neutrophils and macrophages within the airways with a Th1 lymphocytic population. The GPCR signature (transcriptomic) will be determined on total white blood cells as well as on isolated mono- and poly-nuclear populations obtained from healthy subjects and patients selected at the asthma or COPD consultation. The expression profiling analysis will reveal sub-groups of GPCRs whose expression is modified in disease. The specificity of the variation of expression of these biomarker sub-populations will be determined, by a study recruiting a hundred patients and controls per disease on this restraint number of genes. The outcomes of the project will lead to establish GPCR "identity cards" for these chronic inflammatory diseases, which might therefore be used as diagnostic or prognostic biomarkers to follow the evolution of a disease or the efficacy of a given treatment. In addition, detailed analysis of the identified GPCRs will lead to propose new therapeutic targets for inflammatory diseases. This study has therefore the objective of validating GPCRs as potential biomarkers for inflammatory diseases.

Detailed Description

Multicentre non-randomized

Study Timeline

• Study Start: 2008-09
• Study First Submitted: 2008-11-17
• Study First Submitted QC: 2008-11-18
• Study First Posted: 2008-11-19
• Status Verified: 2017-09
• Primary Completion: 2017-09
• Study Completion: 2017-09
• Last Update Submitted: 2017-09-07
• Last Update Posted: 2017-09-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 205

Inclusion Criteria

• Asthma group
• COPD group
• Control group

Exclusion Criteria

• Patients with infection or inflammatory diseases

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
A= Asthma	blood test	-
C= Control	blood test	-
A= Asthma	spirometry	-
B= COPD	blood test	-

Primary Outcome Measures

Name	Time	Method
differential expression of GPCRs	1 day

Trial Locations

Locations (5)

Hospital; 🇫🇷 Colmar, France

Antoine Magnan; 🇫🇷 Nantes, France

Pascal Chanez; 🇫🇷 Marseille, France

University Hospital; 🇫🇷 Montpellier, France

University Hospital, Strasbourg, France; 🇫🇷 Strasbourg, France